AI-driven Exscientia and Apeiron Enter Oncology Joint Venture

Aitechpark22 Jul, 2021Technology

Combines Exscientia?s leading AI-driven drug identification and design capabilities with GT Apeiron?s expertise in cyclin-dependent kinase (CDK) targets for oncology Expands existing CDK7 drug discovery partnership with additional CDK targeting drugs Exscientia, an AI-driven pharmatech company with a mission to revolutionise how drugs are discovered, and GT Apeiron Therapeutics ?Apeiron?, a Shanghai based company focused on novel oncology drugs, announced today a strategic research and development collaboration agreement. The collaboration will leverage the patient-centric AI-first capabilities of Exscientia to accelerate the discovery of multiple small molecule therapeutic drug candidates designed to selectively treat aberrant cell cycle driven cancers and build a pipeline of CDK novel therapies. All pipeline products will be equally owned and Exscientia holds an equity stake in Apeiron.